<DOC>
	<DOCNO>NCT00858403</DOCNO>
	<brief_summary>The main purpose study learn patient Advanced Non-Small Cell Lung Cancer ( NSCLC ) respond study drug Dasatinib . The study drug , Dasatinib , approve U.S. Food Drug Administration ( FDA ) treatment leukemia , approve treatment kind cancer . The use Dasatinib study consider experimental .</brief_summary>
	<brief_title>Dasatinib Advanced Non-small Cell Lung Cancer ( NSCL ) With Ex Vivo In Vivo Assessment Tumor Target Modulation</brief_title>
	<detailed_description>Cycle 1 Day 1 ( C1D1 ) : Patients complete history physical ( H &amp; P ) , complete blood count ( CBC ) , complete metabolic panel ( CMP ) electrocardiogram ( EKG ) day 1 . Each cycle 28 day . The C1D1 EKG omit patient new cardiac symptom start take medication know affect QT correct heart rate ( QTc ) prolongation . Any residual toxicity prior therapy cancer record . Blood drawn assessment serum marker . The patient begin dasatinib start C1D1 daily basis . Cycle 1 Day 10-20 ( C1D10-20 ) : Patients second biopsy obtain additional tumor material examine biological effect dasatinib signal pathway . Dasatinib take first thing morning patient log time . Blood also draw pharmacokinetic assessment dasatinib level plasma time record . Four FNA aspirate 2 core biopsy obtain either bedside palpable lesion appropriate image-guided technique ( CT US ) discretion treat physician consultation radiology . The time biopsy record . One core biopsy immediately fix formalin core biopsy snap frozen liquid nitrogen . Cycle 2 Day 1 ( C2D1 ) : Patients see treat physician complete H &amp; P , CBC , CMP . Blood drawn assessment serum marker . Toxicity dasatinib assess . The patient continue take daily dos dasatinib daily basis . Cycle 2 Day 22 ( C2D22 ) : Patients undergo reevaluation tumor measurement . This assessment occur C2D22 ±7 day .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Histologically cytologically document diagnosis NSCLC advanced/metastatic ( Stage IIIB/IV ) . Performance Status ( ECOG ) 02 Previous chemotherapy exception dasatinib . Patients type previous chemotherapy regimens nonsmall cell lung cancer eligible . Adequate Organ Function : Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ( ULN ) Hepatic enzyme ( AST , ALT ) ≤ 2.5 time institutional ULN Serum Na , K+ , Mg2+ , Phosphate Ca2+≥ Lower Limit Normal ( LLN ) Serum Creatinine &lt; 1.5 time institutional ULN Hemoglobin , Neutrophil count , Platelets , prothrombin time ( PT ) , partial thromboplastin time ( PTT ) Grade 01 Ability take oral medication Concomitant Medications : Agree discontinue St. Johns Wort receive dasatinib therapy Agree IV bisphosphonates withhold first 8 week dasatinib therapy due risk hypocalcemia . Women childbearing potential ( WOCBP ) : A negative serum urine pregnancy test within 72 hour prior start study drug administration Persons reproductive potential must agree use utilize adequate method contraception throughout treatment least 4 week study drug stop Prior study enrollment . Signed write informed consent include HIPAA form accord institutional Guidelines No malignancy [ one treat study ] require radiotherapy systemic treatment within past 5 year . Prior dasatinib therapy . Concurrent medical condition may increase risk toxicity , include : Patients severe pulmonary disease increase risk toxicity relate dasatinibinduced pleural effusion . This include chronic obstructive pulmonary disease pleural effusion ( malignant benign ) require chronic oxygen therapy patient prior pneumonectomy . Patients pulmonary embolism require oxygen therapy exclude patient pulmonary embolism require oxygen therapy . Patients active pleural effusion control pleurodesis exclude . Cardiac Symptoms ; follow consider exclusion : Uncontrolled angina , congestive heart failure MI within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Patients hypokalemia hypomagnesemia correct prior dasatinib administration History significant bleeding disorder unrelated cancer , include : Diagnosed congenital bleeding disorder Diagnosed acquire bleed disorder within one year Ongoing recent ( ≤ 3 month ) significant gastrointestinal bleeding Concomitant Medications , follow consider exclusion : Category I drug generally accept risk cause Torsades de Pointes include : ( Patients must discontinue drug 7 day prior start dasatinib ) 1. quinidine , procainamide , disopyramide 2. amiodarone , sotalol , ibutilide , dofetilide 3. erythromycin , clarithromycin 4. chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide 5. cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . Women : unwilling unable use acceptable method avoid pregnancy entire study period least 4 week cessation study drug , positive pregnancy test baseline pregnant breastfeeding Prisoners person compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness Patients systemic anticoagulation risk bleed related tumor biopsy anticoagulation per discretion physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Advanced Non-small Cell Lung Cancer</keyword>
</DOC>